Catalent, Inc. Reports Second Quarter Fiscal 2021 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. ACN
6. NTMFF
7. III
8. SAN
9. TTEC
10. SNY

Go back to Catalent, Inc. Reports Second Quarter Fiscal 2021 Results

Catalent (CTLT) PT Raised to $137 at RBC Capital, 'COVID-Related Programs Continue to Drive FY21 Outlook Higher'

February 2, 2021 4:20 PM EST

RBC Capital analyst Sean Dodge raised the price target on Catalent (NYSE: CTLT) to $137.00 (from $125.00) while maintaining a Outperform rating.

The analyst comments "F2Q21 results were ahead of consensus on another strong quarter of organic revenue growth (65% YoY) and EBITDA margin expansion... More

Catalent (CTLT) Tops Q2 EPS by 8c, Revenues Beat; Raises FY21 Revenue Guidance Above Consensus

February 2, 2021 7:17 AM EST

Catalent (NYSE: CTLT) reported Q2 EPS of $0.63, $0.08 better than the analyst estimate of $0.55. Revenue for the quarter came in at $910.8 million versus the consensus estimate of $894.58 million.

Q2'21 net revenue of $910.8 million increased 26% as-reported, or 24% in constant currency, compared to Q2'20. Organic, constant currency net revenue grew 17%, compared to Q2'20.Q2'21 net earnings of $88.4 million increased 94%, or 88% in constant currency, compared to Q2'20.Q2'21 Adjusted EBITDA of $223.5 million increased 31% as-reported, or 28% in constant currency, compared to Q2'20.Q2'21 Biologics segment net... More